Isis Pharmaceuticals Reports Final Phase 2 Data on ISIS-GCGR RX Showing Significant Reduction in HbA1c in Patients with Type 2 Diabetes.

Isis Pharmaceuticals announced the final results from its Phase 2 study of ISIS-GCGRRx in patients with type 2 diabetes uncontrolled on stable metformin therapy. This Phase 2 study of ISIS-GCGRRx was a double-blinded, randomized, placebo-controlled study in 75 patients with type 2 diabetes who had uncontrolled blood sugar despite treatment with stable metformin therapy. Patients  in the per protocol population (PP) treated with ISIS-GCGRRx for 13 weeks in addition to metformin achieved absolute mean reduction in hemoglobin A1c (HbA1c) and  fructosamine.. ISIS-GCGRRx was generally well tolerated in this study without impact on liver function or weight gain.

ISIS-GCGRRx is an antisense drug designed to inhibit GCGR, a receptor for the hormone, glucagon, that opposes the action of insulin and stimulates the liver to produce glucose.

Company presented these results at American Diabetes Association annual meeting.